Leukemia, Lymphocytic, Chronic, B-Cell
Oncology·MeSH: Leukemia, Lymphocytic, Chronic, B-Cell
Prevalence
30.0 / 100K
4 drugs in development·3 companies·6 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Venetoclax | Merck & Co., Inc. (MRK) |
Phase 1(2)
Phase 4(1)
| Drug | Company |
|---|---|
| Pirtobrutinib | ELI LILLY & Co (LLY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Leukemia, Lymphocytic, Chronic, B-Cell?
BioSniper tracks 4 drugs in development for Leukemia, Lymphocytic, Chronic, B-Cell across 3 companies.
How many clinical trials target Leukemia, Lymphocytic, Chronic, B-Cell?
There are 6 clinical trials targeting Leukemia, Lymphocytic, Chronic, B-Cell tracked by BioSniper.
What is the prevalence of Leukemia, Lymphocytic, Chronic, B-Cell?
The estimated prevalence of Leukemia, Lymphocytic, Chronic, B-Cell is approximately 30.0 per 100,000 population.
Deep-dive into Leukemia, Lymphocytic, Chronic, B-Cell
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis